Hong Kong Luxury Stock News

Country Garden Holdings (SEHK:2007) has reported full year 2025 results with sales of CN¥154,893 million and net income of CN¥3,261 million, alongside board-backed plans to update its Articles of Association. See our latest analysis for Country Garden Holdings. The latest results and governance updates come after a mixed share price pattern, with a 1 day share price return of 1.61% and a 90 day share price return showing a 14.86% decline, while the 5 year total shareholder return indicating a...

Wondering if Sun Hung Kai Properties at HK$138.30 is offering genuine value or just reflecting market excitement? This article walks through what the current price might be telling you. The stock has posted returns of 2.7% over the last 7 days, 1.0% over the past month, 43.2% year to date, and 116.8% over the last year, which has put it firmly on many investors' radar. Recent coverage has focused on Sun Hung Kai Properties as one of Hong Kong's large property names, with attention on how it...

Dividend changes, earnings and Kazakhstan build out put Fufeng Group in focus Fufeng Group (SEHK:546) is back on investors' radar after reporting full year 2025 results, proposing both a special and ordinary dividend, and updating progress on its Kazakhstan production base. For the year ended 31 December 2025, Fufeng Group reported sales of CN¥27,879.19 million and net income of CN¥2,465.23 million. Basic earnings per share from continuing operations were CN¥0.9833, while diluted earnings per...

MicroPort Scientific reported full-year 2025 sales of US$994.91 million and net income of US$48.52 million, while announcing that long-time chairman Dr. Zhaohua Chang stepped down as CEO and was replaced by rotating chief executive Jonathan W. Chen alongside the creation of a new Global Executive Committee and a new company secretary. This combination of a turnaround to profitability with a refreshed leadership and governance structure highlights MicroPort Scientific’s push to align...

Earnings and dividend announcement set the tone Dah Sing Banking Group (SEHK:2356) has attracted fresh attention after reporting full year 2025 results and proposing an ordinary final dividend of HK$0.49 per share, subject to shareholder approval in June 2026. See our latest analysis for Dah Sing Banking Group. The dividend and earnings news comes after a strong run, with Dah Sing Banking Group’s share price returning 6.46% over the past month and 19.96% over 90 days, while its 1-year total...

Kuaishou Technology (SEHK:1024) shares moved after the company reported quarterly and full year 2025 earnings, together with a recommended final dividend, giving investors fresh data on cash generation, shareholder returns and recent business performance. See our latest analysis for Kuaishou Technology. The latest 4.01% 1 day share price return, to HK$46.7, comes after a tougher few months, with a 30 day share price return of 22.87% decline and a 90 day share price return of 35.05% decline...

Air China has launched a new direct passenger route between Chengdu and Brussels, creating a fresh air link between China and Belgium. The service is intended to support international connectivity and contribute to the recovery of inbound tourism in Chengdu. The new route forms part of Air China’s wider international network development and aligns with local infrastructure and travel facilitation efforts. For investors tracking Air China (SEHK:753), the new Chengdu to Brussels route lands...

Phase 2 data on UBT251 puts United Laboratories International Holdings in focus United Laboratories International Holdings (SEHK:3933) drew investor attention after releasing phase 2 data for UBT251 in China, showing HbA1c and body weight reductions against placebo and semaglutide in type 2 diabetes patients. The topline readout matters because it moves UBT251 closer to late stage development, supports the start of phase 3 trials in China, and ties directly into the company’s broader diabetes...

China Mengniu Dairy (SEHK:2319) has come into focus after releasing its full year 2025 results and proposing a final ordinary dividend of RMB 0.52 per share, subject to shareholder approval. See our latest analysis for China Mengniu Dairy. The latest earnings and dividend proposal appear to have supported sentiment, with a 30 day share price return of 6.36% and a 90 day share price return of 14.41% lifting the stock to HK$17.55. This comes even though the 1 year total shareholder return is a...

China Star Entertainment (SEHK:326) just released full year 2025 results showing revenue of HK$404.92 million and a net loss of HK$443.76 million, broadly in line with guidance for a sizeable annual loss. See our latest analysis for China Star Entertainment. The weak 2025 results come after a sharp re-rating in the market, with the share price at HK$6.70 and a 30 day share price return of 45.34%. This has fed into a very large 1 year total shareholder return, suggesting momentum has been...

Simcere Pharmaceutical Group (SEHK:2096) has drawn fresh attention after reporting full year 2025 sales of CN¥7,731.41 million and net income of CN¥1,344.01 million, alongside a proposed final dividend of CN¥0.18 per share. See our latest analysis for Simcere Pharmaceutical Group. At a latest share price of HK$13.62, Simcere Pharmaceutical Group has seen a 16.91% 1 month share price return and an 80.98% 1 year total shareholder return. Recent earnings, dividend and leadership announcements...

Today is shaping up negative for Contiocean Environment Tech Group Co., Ltd. ( HKG:2613 ) shareholders, with the...

Sinotruk (Hong Kong) (SEHK:3808) has drawn fresh attention after reporting full year 2025 results with higher sales and net income, along with a board proposal to lift the ordinary final dividend for shareholders. See our latest analysis for Sinotruk (Hong Kong). The share price has responded strongly, with a 30 day share price return of 14.48% and a 90 day gain of 51.71%. The 1 year total shareholder return of 137.59% points to building momentum around the healthier earnings and higher...

Ubtech Robotics Corp Ltd ( HKG:9880 ) shareholders will have a reason to smile today, with the analysts making...

Market forces rained on the parade of NetDragon Websoft Holdings Limited ( HKG:777 ) shareholders today, when the...

Today is shaping up negative for Kingsoft Corporation Limited ( HKG:3888 ) shareholders, with the analysts delivering a...

One thing we could say about the analysts on West China Cement Limited ( HKG:2233 ) - they aren't optimistic, having...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

One thing we could say about the covering analyst on Beijing Chunlizhengda Medical Instruments Co., Ltd. ( HKG:1858...

The latest analyst coverage could presage a bad day for China Datang Corporation Renewable Power Co., Limited...

Jiaxin International Resources Investment Limited ( HKG:3858 ) shareholders will have a reason to smile today, with the...

Earnings shift draws fresh attention to InnoCare Pharma InnoCare Pharma (SEHK:9969) has drawn fresh attention after reporting full year 2025 sales of CN¥2,374.91 million and net income of CN¥642.47 million, compared with a net loss a year earlier. See our latest analysis for InnoCare Pharma. The earnings swing has coincided with strong price momentum, with a 31.19% 1 month share price return and a 24.16% year to date share price return at HK$15.52. The 1 year total shareholder return of...

Fosun International (SEHK:656) has come under closer focus after reporting a larger net loss for 2025, withholding a dividend for the year, and outlining a higher dividend payout framework starting from the 2026 financial year. See our latest analysis for Fosun International. The recent dividend decision and larger 2025 net loss come after a mixed share price pattern, with a 19.5% 1 month share price return and a 9.91% 1 year total shareholder return contrasting with weaker multi year total...

Recent share performance and business snapshot Ascentage Pharma Group International (SEHK:6855) has drawn investor attention after recent share price moves, with returns of about 13% over the past week and 15% over the past month. The Suzhou based clinical stage biotech focuses on therapies for cancers, chronic hepatitis B and age related diseases in Mainland China. It generated HK$574.12 million in revenue and reported a net loss of HK$1,242.77 million. See our latest analysis for Ascentage...